Sironax Ltd.

WALTHAM, Mass.--(BUSINESS WIRE)-- X-Chem, the global leader in DNA-encoded library (DEL) technology, today announces the establishment of a research partnership with Sironax, in which X-Chem will leverage its powerful DEL platform to support Sironax’s drug discovery pipeline. Through the collaboration, X-Chem will screen its unique DNA-encoded libraries against difficult-to-drug targets implicated in neurodegenerative disease to discover hits. In turn, Sironax will prosecute these hits into transformational medicines for degenerative disease. “We appreciate being a preferred partner to support drug discovery projects across the Sironax portfolio,” said X-Chem CEO Matt Clark. “The combination of Sironax’s deep scientific knowledge and our leading DEL platform will help drive the discovery of new therapeutics that will help patients.” About X-Chem X-Chem, Inc. is the leader in small molecule discovery science, providing pharmaceutical and biotech companies a complete, seamless solution for screening, hit validation and lead optimization. As pioneers of DNA-encoded chemical library (DEL) technology, the company leverages its market-leading DEL platform to discover novel small molecule leads against challenging, high-value therapeutic targets. In-house lead optimization services enable clients to progress their compounds directly for even higher quality outputs. Our expertise in medicinal chemistry, custom synthesis and scale-up process chemistry enables us to support all aspects of drug discovery, supporting lead optimization through candidate identification. About Sironax Sironax is a clinical-stage biotechnology company dedicated to the discovery and global development of novel treatments for patients with age-related degenerative diseases. Since its founding in 2017, Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways and neuroinflammation. Sironax is currently conducting early clinical studies with SIR0365 and SIR2446, in addition to ongoing preclinical research. For more information, please visit .

GluBio Adds $22M for TPD Platform Investors Pour $120M into OriCell's Cancer Immunology Efforts Sironax Bolsters Fight against Degenerative Diseases with $200M Series B Existing Stockholders Prop Up AEON's Botulinum Injection Core Biogenesis Win $10.5M for Environmentally Friendly Model There are many more shots on cancer this week as funding went to oncology-focused companies such as GluBio and Shanghai-based OriCell. China-based Sirolax scooped up a whopping $200 million to fight degenerative diseases, and French Core Biogenesis is building a new manufacturing facility for eco-friendly growth factor production. GluBio Adds $22M for TPD Platform After a Series A+ financing round, GluBio Therapeutics added another $22 million, bringing its total assets to almost $90 million. The biotech company focuses on developing novel targeted protein degradation (TPD) drugs, and with this latest cash boost, it now has the resources to launch two molecular glue degrading products to clinical stages. Both are intended to help treat hematological malignancies. The new funds will also go toward upgrading the company's proprietary TPD platform, which identifies small-molecule protein degraders and accelerating lead optimization for three more assets targeting solid tumors and inflammatory diseases. Investors Pour $120M into OriCell's Cancer Immunology Efforts Cancer immunology company OriCell Bio closed a victorious Series B financing round with the equivalent of USD$120 million. The Shanghai-based company had support from major Chinese investors such as Qiming Venture Partners, Quan Capital and C&D Emerging Capital. Some of the funding will help OriCell to build a new manufacturing plant and advance its discovery platform. It will also support the development of Ori-C101, a chimeric antigen receptor T cell (CAR-T) product intended to treat liver cancer, which was recently accepted as an investigational new drug by the National Medical Products Administration (NMPA) of China. OriCell also needs the funds to advance OriCAR-017, a CAR-T treatment for relapsed and refractory multiple myeloma, through clinical development in both the U.S. and China. Sironax Bolsters Fight against Degenerative Diseases with $200M Series B Also in Beijing, Sironax scooped up roughly $200 million in a Series B round of financing, led by Gaorong Capital and Yunfeng Capital. The biotech company develops treatments for age-related degenerative diseases and so far, it has garnered more than $300 million in funding. Sironax said it plans to use the money to expand R&D and pipeline efforts, especially for the clinical development of its portfolio of RIPK1 inhibitors. The funding will also go toward advancing programs that study the underlying mechanisms of age-related degenerative diseases, such as regulated cell death, neuroprotective pathways and neuroinflammation. "We have built a robust pipeline of novel programs of both small molecules and biologics that target critical pathways underlying degenerative disease pathogenesis," Sironax CEO Aaron Ren, Ph.D. said. "With this investment, we are well-positioned to advance additional programs into the clinic and continue to move our lead program forward." Existing Stockholders Prop Up AEON's Botulinum Injection California-based AEON Biopharma has investors that are so committed they put an additional $30 million into an unsecured convertible note. This brings total insider investments to $54.5 million since December 2021. The funding aims to advance ABP-450, AEON's proprietary botulinum toxin complex for therapeutic indications. The toxin works by blocking peripheral acetylcholine release at presynaptic cholinergic nerve terminals. Currently, AEON is testing the product's effectiveness in treating cervical dystonia, chronic migraine and episodic migraine in Phase II clinical trials. Core Biogenesis Win $10.5M for Environmentally Friendly Model French biotech company Core Biogenesis completed a Series A round of financing with about $10.5 million. The primary focus of the funding will be to build an industrial-scale facility that produces growth factors and cytokines for cell therapy. Core Biogenesis is unique because of its plant-based molecular farming platform, in which proteins from oilseed plants produce highly bioactive compounds. These compounds can be used in cell culture media components and cell therapy manufacturing without the need for animal products. "Not only can we produce proteins at high yield and lower cost than traditional methods, but our entire production process is carbon-negative. At Core Biogenesis, we truly believe that what is good for the patient can also be good for the planet," CSO and Co-founder Chouaib Meziadi said.

Financing from new and existing investors will support pipeline progression and expansion for age-related degenerative diseases BEIJING, Aug. 2, 2022 /PRNewswire/ -- Sironax, an emerging biotechnology company dedicated to the discovery and global development of novel treatments for patients with age-related degenerative diseases, today announced the completion of a $200 million Series B financing. The round was led by Gaorong Capital and Yunfeng Capital, with participation from existing investors including Temasek, Invus, F-Prime Capital, Eight Roads, ARCH Venture Partners, K2 Venture Partners and lead investors from previous financings. In addition to the co-leads, new investors include MSA Capital, CBC Group, Long River Investments, LSV Capital, Superstring Capital, and Future Innovation Fund as well as a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA). With the closing of this round, the Company has raised over $300 million to date. Sironax's pipeline is comprised of multiple programs with a focus on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways and neuroinflammation. Sironax plans to use the proceeds to support the ongoing clinical development of its portfolio of receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors in addition to the continued expansion of its R&D footprint and pipeline of potential best- and first-in-class candidates for age-related degenerative diseases. "We are pleased to be supported by a syndicate of leading investors to enable us to achieve our vision of bringing transformational therapies to patients around the globe whose lives are impacted by a broad range of degenerative diseases," said Aaron Ren, Ph.D., Chief Executive Officer of Sironax. "Building upon groundbreaking discoveries—including many by our co-founder Dr. Xiaodong Wang—we have built a robust pipeline of novel programs of both small molecules and biologics that target critical pathways underlying degenerative disease pathogenesis. With this investment, we are well-positioned to advance additional programs into the clinic and continue to move our lead program forward." Dr. Albert Huang, Managing Director at Yunfeng Capital noted, "The fast-growing aging population leads to a high demand for the therapy of age-related degenerative diseases. Over the past 20 years, Dr. Xiaodong Wang has devoted himself to programmed cell death research, unearthing a novel mechanism of aging and degenerative disease, which has laid the foundation of scientific success for Sironax. We look forward to a lasting partnership with Dr. Wang, Dr. Ren and the entire Sironax team, and strongly believe the Company has the potential to develop effective solutions for age-related degenerative diseases." A representative from Gaorong Capital commented: "The demands for clinical development and effective therapies are increasing along with the deepened understanding in degenerative diseases. As a fast-growing clinical-stage company, Sironax has established a robust pipeline targeting degenerative diseases, which has demonstrated strong safety pro promising efficacy signals in early clinical trials. We are delighted to work with the Sironax team and support the advancement of therapies for degenerative diseases that could offer benefits to patients around the world and increase their quality of life." About Sironax Sironax is a clinical-stage biotechnology company dedicated to the discovery and global development of novel treatments for patients with age-related degenerative diseases. Since its founding in 2017, Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways and neuroinflammation. Sironax is currently conducting early clinical studies with SIR0365 and SIR2446, in addition to ongoing preclinical research. For more information, please visit About Gaorong Capital Founded in 2014, Gaorong Capital is focused on early and growth-stage investments, with a specialty in new consumption, new technology and healthcare. We have 20 IPO portfolios and over 30 projects valued more than USD 1 billion, amongst which, many of them have advanced to be leaders in their perspective industries, including Pinduoduo, Huya, BOSS Zhipin, Roborock, Dingdong Fresh, etc. We continue to invest in the healthcare industry, and are committed to discovering and accompanying leading companies in the fields of digital health, medical services, drug discovery, medical instrumentation and testing. About Yunfeng Capital Founded in 2010, Yunfeng Capital is a leading private equity investment firm in China committed to fostering future-ready companies. With a common vision for building a better future, we work side by side with entrepreneurs to create long-term value. We have formed deep sector expertise and industry insights in our focused sectors, including Technology, Business Services, Green Energy, Digital Agriculture, Biotechnology and Consumption, and we are dedicated to promoting technological innovation and sustainable development to enable and to drive industry transformation and upgrade.